References
- Lock M. Symptom reporting at menopause: a review of cross cultural findings. J Br Menopause Soc 2002;8:132–6
- Stearns V, Ullmer L, Locpez JF, etal. Hot flushes. Lancet 2002;360:1851–61
- Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990;592:52–86
- Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319–36
- Pearce J, Hawton K, Blake F. Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Br J Psychiatry 1995;167:163–73
- Montgomery JC, Studd JW. Psychological and sexual aspects of the menopause. Br J Hosp Med 1991;45:300–2
- MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001; 4:58–74
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initia-tive randomised controlled trial. J Am Med Assoc 2002;288:321–33
- Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: a 5 year randomised trial. Maturitas 1998;31: 45–54
- Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmeno-pausal women in the United States. Ann Intern Med 1999;130:545–53
- Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance. Obstet Gynecol 1997;90:269–77
- Hope S, Wager E, Rees MCP. Survey of British women's views on the menopause and HRT. J Br Menopause Soc 1998;4;33–6
- Li C, Samsioe G, Lidfelt J, Nerbrand C, Agardh CD. Important factors for use of hormone re-placement therapy: a population-based study of Swedish women. The Women's Health in Lund Area ( WHILA) Study. Menopause 2000;7: 273–81
- EMEA. Points to consider on hormone replace-ment therapy (CPMP/EWP/021/97), Committee for Proprietary Medicinal Products, London, November 1997
- Van Gorp T, Neven P. Endometrial safety of hormone replacement therapy: review of litera-ture. Maturitas 2002;42:93–104
- Rees MCP, Hope S. Why do British women start and stop HRT? J Br Menopause Soc 1995;1:26–7
- Good clinical practice of clinical trials on medicinal products in the European Community. In The Rules Governing Medicinal Products in the European Community, Vol III (Addendum), July 1990 (Directive 91/507/EEC)
- Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of female genital tract tumours. In Scully RE, Poulsen HE, Sobin L, eds. International Histological Classification of Tumours, 2nd edn. Berlin: Springer-Verlag, 1994
- Sturdee DW, van de Weijer P, von Holst T. Endometrial safety of a transdermal sequential estradiol—levonorgestrel combination. Climacteric 2002;5:170–7
- Ferenczy A, Gelfand MM, van de Weijer PH, Rioux JE. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 1713-estradiol combined with sequential 5-20 mg dydrogesterone. Climacteric 2002;5:26–35
- Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89:1765–72
- Sporrong T, Rybo G, Mattsson LA, Vilbergson G, Crona N. An objective and subjective assess-ment of uterine blood loss in postmenopausal women on hormone replacement therapy. Br J Obstet Gynaecol 1992;99:399–401
- Marslew U, Munk-Nielsen N, Nilas L, Riis BJ, Christiansen C. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas 1994; 19:225–37
- Rees MCP. The uterus and the menopause. Baillière's Clin Obstet Gynaecol 1996;10: 419–32
- Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 170-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726–31
- Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for perimenopausal and postmenopausal women: weight and body fat distribution. Cochrane Database Syst Rev 2000;2:CD001018
- Godsland IF. Effects of postmenopausal hor-mone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898–915